Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib safety as second-line therapy in hepatocellular carcinoma excluded from RESORCE
jRCTs031190103Completed
- Sponsor
- Bayer
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of regorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Bayer. Primary endpoints: Time to progression (mRECIST) and Time to progression (RECIST 1.1). Started Jan 2020; status: completed.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031190103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190103.